Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $21.41 USD
Change Today -0.20 / -0.93%
Volume 100.0
GIKLY On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

grifols sa-spon adr (GIKLY) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $23.59
52 Week Low
10/15/14 - $18.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GRIFOLS SA-SPON ADR (GIKLY)

Related News

No related news articles were found.

grifols sa-spon adr (GIKLY) Related Businessweek News

No Related Businessweek News Found

grifols sa-spon adr (GIKLY) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, and software for use in diagnostic and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by and in hospitals, such as parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

13,993 Employees
Last Reported Date: 02/26/15
Founded in 1940

grifols sa-spon adr (GIKLY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa-spon adr (GIKLY) Key Developments

Grifols, S.A. Jointly with Ortho Clinical Diagnostics Enter into Restated and Extended Contract with Abbott for Production of Current Antigens in Addition to Five New Ones in its Manufacturing Facility in Emeryville, California

Grifols, S.A. announced that it has signed, jointly with Ortho Clinical Diagnostics, a restated and extended contract through 2026 with Abbott for the production of current antigens in addition to five new ones in its manufacturing facility in Emeryville, California. The new contract, which extends manufacturing services through 2026, has a total value approximating $700 million. The new facility for the manufacture of recombinant antigens utilized in clinical diagnosis and blood screening, dubbed Project Horizon, is expected to be completed and licensed by the beginning of 2017. Until the new facility is completed and licensed, the antigens will continue to be produced in Grifols’ existing manufacturing facility in Emeryville.

Grifols, S.A. - Shareholder/Analyst Call

Grifols, S.A. - Shareholder/Analyst Call

Grifols, S.A. Reports Unaudited Consolidated Group Earnings Results for the First Quarter Ended March 31, 2015

Grifols, S.A. reported unaudited consolidated group earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues were EUR 908.4 million against EUR 798.0 million a year ago. EBITDA was EUR 280.0 million against EUR 270.2 million a year ago. EBIT was EUR 236.4 million against EUR 223.9 million a year ago. Group net profit was EUR 236.4 million against EUR 223.9 million a year ago. Adjusted group net profit was EUR 148.7 million against EUR 147.0 million a year ago. Capex was EUR 68.3 million against EUR 45.7 million a year ago. Earnings per share were EUR 0.38 against EUR 0.35 a year ago. At the end of the first quarter of 2015, net financial debt amounted to EUR 3,981.0 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIKLY:US $21.41 USD -0.20

GIKLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $149.45 USD +3.00
Endo International PLC $87.63 USD +1.82
H Lundbeck A/S kr156.50 DKK -2.50
Hospira Inc $89.23 USD -0.12
UCB SA €67.00 EUR -2.50
View Industry Companies

Industry Analysis


Industry Average

Valuation GIKLY Industry Range
Price/Earnings 28.2x
Price/Sales 3.9x
Price/Book 4.3x
Price/Cash Flow 17.6x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at